Travere Therapeutics, Inc.

Travere Therapeutics Chief Research Officer William Rote, Ph.D. provided notice on June 12, 2026 of his retirement effective February 17, 2027, the 10-year anniversary of his employment; he will remain in his current role and assist with transition through the Retirement Date. No successor CRO is named in the excerpt. Orderly planned departure with 8+ months of notice; the lengthy notice period suggests internal succession planning is underway, though the CRO role is material for a company mid-development on civorebrutinib and other pipeline assets.

Travere Therapeutics entered a license and collaboration agreement with Everest Medicines (Singapore) Pte. Ltd. on June 1, 2026 under which Everest grants Travere exclusive, royalty-bearing rights to develop and commercialize civorebrutinib (EVER001), a covalent reversible BTK inhibitor, in all fields across all countries outside China and certain East/Southeast Asian territories. Travere gains rights to make, import, distribute, sell, and develop the compound globally ex-Asia, with rights including a sublicense to third-party IP. Financial terms (upfront, milestones, royalties) are not disclosed in the excerpt. Material in-licensing deal — civorebrutinib adds a BTK inhibitor to Travere's pipeline, complementing its rare kidney disease focus, likely funded by the concurrent $525M convertible note raise.

Travere Therapeutics held its 2026 Annual Meeting at which stockholders approved an amendment to the 2018 Equity Incentive Plan increasing the authorized share pool by 3,000,000 shares; this is disclosed under Item 5.02 as a compensatory arrangement approval. Item 5.07 covers the broader Annual Meeting voting results. Additional annual meeting proposals beyond the equity plan are described in the proxy but their vote outcomes are not fully detailed in the excerpt. The 3M share addition provides equity compensation runway; mildly dilutive.

Travere Therapeutics completed a $525 million registered underwritten offering of 0.50% Convertible Senior Notes due May 15, 2032 on May 11, 2026, including $50M from full exercise of the underwriters' overallotment (underwriters: J.P. Morgan, Jefferies, Leerink Partners). Notes are redeemable at Travere's option from May 21, 2029 onward if the stock exceeds 130% of the conversion price; settlement in cash, shares, or a combination. Items 2.03/3.02 cover the debt creation and private placement aspects; Item 8.01 likely covers a concurrent capped call transaction to limit dilution above the conversion premium. A large-scale capital raise at low cost of debt — the $525M will fund pipeline development including the Everest BTK inhibitor license and commercial FILSPARI activities.

Travere Therapeutics filed a 424B5 prospectus supplement for $475 million of 0.50% Convertible Senior Notes due May 15, 2032 at 100% issue price (with $50M underwriter greenshoe option). Conversion is permitted under specified stock price and trading triggers; notes are redeemable from May 21, 2029 onward if the stock exceeds 130% of the conversion price; settlement in cash, shares, or a combination at Travere's option. This is the pricing prospectus for the convertible offering, which was ultimately upsized to $525M following full exercise of the overallotment (see Job 45). The offering provides long-term capital at a low 0.50% coupon with dilution contingent on stock performance above the conversion premium.

Travere Therapeutics filed an earlier 424B5 prospectus supplement for $400 million (with $60M greenshoe option) of convertible senior notes due 2032; the coupon and conversion price fields appear as blank placeholders in the excerpt, indicating this was a preliminary or term-pending filing before pricing was finalized. This preliminary prospectus was superseded by the final $475M pricing prospectus (Job 49) and the ultimately closed $525M offering (Job 45). Administrative/preliminary filing for Travere's convertible note offering process.